Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis

Brentuximab vedotin (BV) monotherapy (BV-M) and combination (BV-C) therapies are safe and effective for classical Hodgkin lymphoma (cHL) and CD30-expressing peripheral T-cell lymphomas (PTCLs). Although the sample sizes have been small (12–29 patients), in clinical studies, response rates of 53–88%...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Dahlia Sano, Nicholas Liu, Scott Knowles, Joanna P. MacEwan, Shu Wang, Jenifer Wogen, Kristina S. Yu, Seung Tae Lee
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2024-05-01
Colecção:	Current Oncology
Assuntos:	cHL CD30-expressing PTCL real-world claims database treatment patterns
Acesso em linha:	https://www.mdpi.com/1718-7729/31/5/195
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!